Fed. Circ. OKs Boston Drug Developer's Patent Win

By Andrew Karpan · March 11, 2024, 8:31 PM EDT

A Boston-area biotech developer that has yet to bring a product to market persuaded the Federal Circuit on Monday to affirm a finding by an administrative patent board last year that...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Order

Case Information

Case Title

Risen (Suzhou) Pharma Tech Co., Ltd. v. Alzheon, Inc.

Case Number

Court

Appellate - Federal Circuit

Nature of Suit

-

Date Filed

September 21, 2022

Recent Articles By Andrew

October 23, 2024
Court Denies Fees In 'Objectively Specious' Trade Secrets Suit
October 02, 2024
Avadel Tells Fed. Circ. It Should Be Free To Test Sleep Drug
September 26, 2024
2nd Circ. Denies Jury Trial In Abbott Labs Gray Market Case
September 09, 2024
Purdue Sees Another OxyContin Patent Axed
September 05, 2024
Nvidia, Microsoft Face Patent, Cartel Allegations In Texas Suit
August 09, 2024
Valeant's Legal Gripe A Total 'Nothingburger,' Justices Told
July 11, 2024
GSK Asks Judge To Rule In Teva IP Case, Citing Opioid Deals
July 09, 2024
South Africa Drops J&J Probe After TB Drug Price Cuts
June 26, 2024
Ga. High Court Told To Skip Inventor's 'Clerical Mistake' Fight
June 13, 2024
IP Forecast: Cooley Atty Faces DQ Bid Over Past Patent Work